|
||||
![]() This is the 19th consecutive quarter that the company, which specializes in anatomic pathology and molecular testing services for pathologists, oncologists and the pharmaceutical industry, has experienced revenue growth, according to Clarient Vice Chairman and CEO Ron Andrews. Clarient is also reporting a spike in case volume – the number of patient cases sent to the lab by physicians – which increased 32 percent to 31,765 cases, and the company's customer base of oncology and pathology practices grew to more than 950 active clients. "Our record of solid revenue growth combined with our third consecutive quarter of operating profit and the new strength of our balance sheet places Clarient at an important inflection point," says Andrews. "We are now extremely well positioned to take advantage of opportunities that strengthen our menu in key cancers and expand our geographic reach." NEXT PAGE >> Related headlines 'OC METRO Minute,' May 7: UC Irvine Medical Center receives $21 million gift from M.A. Douglas Local.com of Irvine releases first quarter financials Aliso Viejo's Valeant sees 17 percent uptick in revenue I-Flow of Lake Forest reports 9 percent revenue jump |
||||